PTGS2 and breast carcinoma: Later, Ashok conducted a case-control study in 2011 on more than 18,000 subjects, in order to evaluate the association between selective COX-2 inhibitor or nonspecific NSAID assumption and the risk of breast cancer development, and the authors reported that the lowest risk was associated with the use of a selective COX-2 inhibitor [100].